The 340B Noncompliance Data Gap Leaves Drug Manufacturers in the Dark

In the function of drug discount programs, noncompliant discounts loom large as a threat to program integrity. Since 2020, concerns about noncompliance have led some of the biggest drug manufacturers in the U.S. to take actions to limit contract pharmacy participation in the 340B program, an issue now under consideration by the courts.